Prevention of wear particle-induced osteolysis by a novel V-ATPase inhibitor saliphenylhalamide through inhibition of osteoclast bone resorption

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Qin, An ^a,b   Cheng, Tak S ^b   Lin, Zhen ^b,c   Cao, Lei ^a   Chim, Shek M ^b   Pavlos, Nathan J ^b   Xu, Jiake ^b   Zheng, Ming Hao ^b   Dai, Ke Rong ^a,d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; BAFILOMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; SALIPHENYLHALAMIDE; UNCLASSIFIED DRUG; AMIDE; ANTIINFECTIVE AGENT; ENZYME INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SALICYLIC ACID DERIVATIVE; TITANIUM;

ACIDIFICATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHROPLASTY; ARTICLE; BONE DISEASE; CALVARIA; CELL DIFFERENTIATION; CONTROLLED STUDY; ENDOPROSTHESIS LOOSENING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PERI IMPLANT OSTEOLYSIS; POLARIZATION; SIGNAL TRANSDUCTION; WEAR PARTICLE OSTEOLYSIS; ANIMAL; CELL POLARITY; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; SKULL;

AMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ARTHROPLASTY, REPLACEMENT; CELL POLARITY; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MICE; NF-KAPPA B; OSTEOCLASTS; OSTEOLYSIS; RANK LIGAND; SALICYLATES; SIGNAL TRANSDUCTION; SKULL; TITANIUM; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 84859595350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034132     Document Type: Article

References (54)

1. Harris WH, (2001) Wear and periprosthetic osteolysis: the problem. Clin Orthop Relat Res pp. 66-70.
2. Teeny SM, York SC, Mesko JW, Rea RE, (2003) Long-term follow-up care recommendations after total hip and knee arthroplasty: results of the American Association of Hip and Knee Surgeons' member survey. The Journal of arthroplasty 18: 954-962.
3. Greenfield EM, Bi Y, Ragab AA, Goldberg VM, Van De Motter RR, (2002) The role of osteoclast differentiation in aseptic loosening. J Bone Miner Res 20: 1-8.
4. Holt G, Murnaghan C, Reilly J, Meek RM, (2007) The biology of aseptic osteolysis. Clin Orthop Relat Res 460: 240-252.
5. Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP, (2007) The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res 454: 251-261.
6. Sundfeldt M, Carlsson LV, Johansson CB, Thomsen P, Gretzer C, (2006) Aseptic loosening, not only a question of wear: a review of different theories. Acta orthopaedica 77: 177-197.
7. Al-Saffar N, Revell PA, (2000) Differential expression of transforming growth factor-alpha and macrophage colony-stimulating factor/colony-stimulating factor-1R (c-fins) by multinucleated giant cells involved in pathological bone resorption at the site of orthopaedic implants. J Orthop Res 18: 800-807.
8. Chiba J, Rubash HE, Kim KJ, Iwaki Y, (1994) The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clin Orthop Relat Res pp. 304-312.
9. Holding CA, Findlay DM, Stamenkov R, Neale SD, Lucas H, et al. (2006) The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials 27: 5212-5219.
10. Jiranek WA, Machado M, Jasty M, Jevsevar D, Wolfe HJ, et al. (1993) Production of cytokines around loosened cemented acetabular components. Analysis with immunohistochemical techniques and in situ hybridization. J Bone Joint Surg Am 75: 863-879.
11. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, et al. (1999) Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol 154: 203-210.
12. Nakashima Y, Sun DH, Trindade MC, Maloney WJ, Goodman SB, et al. (1999) Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am 81: 603-615.
13. Pioletti DP, Kottelat A, (2004) The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. Biomaterials 25: 5803-5808.
14. Rakshit DS, Ly K, Sengupta TK, Nestor BJ, Sculco TP, et al. (2006) Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. J Bone Joint Surg Am 88: 788-799.
15. Xu JW, Konttinen YT, Lassus J, Natah S, Ceponis A, et al. (1996) Tumor necrosis factor-alpha (TNF-alpha) in loosening of total hip replacement (THR). Clin Exp Rheumatol 14: 643-648.
16. Xu JW, Li TF, Partsch G, Ceponis A, Santavirta S, et al. (1998) Interleukin-11 (IL-11) in aseptic loosening of total hip replacement (THR). Scand J Rheumatol 27: 363-367.
17. Asagiri M, Takayanagi H, (2007) The molecular understanding of osteoclast differentiation. Bone 40: 251-264.
18. Clohisy JC, Frazier E, Hirayama T, Abu-Amer Y, (2003) RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. J Orthop Res 21: 202-212.
19. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, et al. (2004) Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 25: 565-573.
20. Haynes DR, Crotti TN, Zreiqat H, (2004) Regulation of osteoclast activity in peri-implant tissues. Biomaterials 25: 4877-4885.
21. Nakashima T, Takayanagi H, (2008) The dynamic interplay between osteoclasts and the immune system. Arch Biochem Biophys 473: 166-171.
22. Baron R, (1989) Molecular mechanisms of bone resorption by the osteoclast. Anat Rec 224: 317-324.
23. Baron R, Neff L, Louvard D, Courtoy PJ, (1985) Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J Cell Biol 101: 2210-2222.
24. Vaananen HK, Zhao H, Mulari M, Halleen JM, (2000) The cell biology of osteoclast function. J Cell Sci 113 (Pt 3): 377-381.
25. Feng S, Deng L, Chen W, Shao J, Xu G, et al. (2009) Atp6v1c1 is an essential component of the osteoclast proton pump and in F-actin ring formation in osteoclasts. Biochem J 417: 195-203.
26. Laitala T, Vaananen HK, (1994) Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase. J Clin Invest 93: 2311-2318.
27. Laitala-Leinonen T, Lowik C, Papapoulos S, Vaananen HK, (1999) Inhibition of intravacuolar acidification by antisense RNA decreases osteoclast differentiation and bone resorption in vitro. J Cell Sci 112 (Pt 21): 3657-3666.
28. Laitala-Leinonen T, Vaananen HK, (1999) Decreased bone resorption, osteoclast differentiation, and expression of vacuolar H+-ATPase in antisense DNA-treated mouse metacarpal and calvaria cultures ex vivo. Antisense Nucleic Acid Drug Dev 9: 155-169.
29. Lee SH, Rho J, Jeong D, Sul JY, Kim T, et al. (2006) v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12: 1403-1409.
30. Li YP, Chen W, Liang Y, Li E, Stashenko P, (1999) Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 23: 447-451.
31. Scimeca JC, Franchi A, Trojani C, Parrinello H, Grosgeorge J, et al. (2000) The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 26: 207-213.
32. Sobacchi C, Frattini A, Orchard P, Porras O, Tezcan I, et al. (2001) The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 10: 1767-1773.
33. Xu J, Cheng T, Feng HT, Pavlos NJ, Zheng MH, (2007) Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis. Histol Histopathol 22: 443-454.
34. Teplova VV, Tonshin AA, Grigoriev PA, Saris NE, Salkinoja-Salonen MS, (2007) Bafilomycin A1 is a potassium ionophore that impairs mitochondrial functions. J Bioenerg Biomembr 39: 321-329.
35. Huss M, Ingenhorst G, Konig S, Gassel M, Drose S, et al. (2002) Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. J Biol Chem 277: 40544-40548.
36. Muller KH, Kainov DE, El Bakkouri K, Saelens X, De Brabander JK, et al. (2011) The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. British journal of pharmacology 164: 344-357.
37. Bowman BJ, Bowman EJ, (2002) Mutations in subunit C of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site. J Biol Chem 277: 3965-3972.
38. Xie XS, Padron D, Liao X, Wang J, Roth MG, et al. (2004) Salicylihalamide A inhibits the V0 sector of the V-ATPase through a mechanism distinct from bafilomycin A1. J Biol Chem 279: 19755-19763.
39. Zuo J, Jiang J, Chen SH, Vergara S, Gong Y, et al. (2006) Actin binding activity of subunit B of vacuolar H+-ATPase is involved in its targeting to ruffled membranes of osteoclasts. J Bone Miner Res 21: 714-721.
40. Kim JM, Min SK, Kim H, Kang HK, Jung SY, et al. (2007) Vacuolar-type H+-ATPase-mediated acidosis promotes in vitro osteoclastogenesis via modulation of cell migration. Int J Mol Med 19: 393-400.
41. Sochart DH, Porter ML, (1997) Long-term results of total hip replacement in young patients who had ankylosing spondylitis. Eighteen to thirty-year results with survivorship analysis. J Bone Joint Surg Am 79: 1181-1189.
42. Drory O, Nelson N, (2006) Structural and functional features of yeast V-ATPase subunit C. Biochim Biophys Acta 1757: 297-303.
43. Holliday LS, Lu M, Lee BS, Nelson RD, Solivan S, et al. (2000) The amino-terminal domain of the B subunit of vacuolar H+-ATPase contains a filamentous actin binding site. J Biol Chem 275: 32331-32337.
44. Lee BS, Gluck SL, Holliday LS, (1999) Interaction between vacuolar H(+)-ATPase and microfilaments during osteoclast activation. J Biol Chem 274: 29164-29171.
45. Nakamura I, Takahashi N, Udagawa N, Moriyama Y, Kurokawa T, et al. (1997) Lack of vacuolar proton ATPase association with the cytoskeleton in osteoclasts of osteosclerotic (oc/oc) mice. FEBS Lett 401: 207-212.
46. Ryu J, Kim H, Lee SK, Chang EJ, Kim HJ, et al. (2005) Proteomic identification of the TRAF6 regulation of vacuolar ATPase for osteoclast function. Proteomics 5: 4152-4160.
47. Clohisy JC, Hirayama T, Frazier E, Han SK, Abu-Amer Y, (2004) NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis. J Orthop Res 22: 13-20.
48. Clohisy JC, Teitelbaum S, Chen S, Erdmann JM, Abu-Amer Y, (2002) Tumor necrosis factor-alpha mediates polymethylmethacrylate particle-induced NF-kappaB activation in osteoclast precursor cells. J Orthop Res 20: 174-181.
49. Liu F, Zhu Z, Mao Y, Liu M, Tang T, et al. (2009) Inhibition of titanium particle-induced osteoclastogenesis through inactivation of NFATc1 by VIVIT peptide. Biomaterials 30: 1756-1762.
50. Xu J, Tan JW, Huang L, Gao XH, Laird R, et al. (2000) Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res 15: 2178-2186.
51. Zhang C, Tang TT, Ren WP, Zhang XL, Dai KR, (2007) Inhibiting wear particles-induced osteolysis with doxycycline. Acta Pharmacol Sin 28: 1603-1610.
52. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, et al. (2003) 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J Bone Miner Res 18: 2159-2168.
53. Wedemeyer C, Xu J, Neuerburg C, Landgraeber S, Malyar NM, et al. (2007) Particle-induced osteolysis in three-dimensional micro-computed tomography. Calcif Tissue Int 81: 394-402.
54. Feng H, Cheng T, Pavlos NJ, Yip KH, Carrello A, et al. (2008) Cytoplasmic terminus of vacuolar type proton pump accessory subunit Ac45 is required for proper interaction with V(0) domain subunits and efficient osteoclastic bone resorption. J Biol Chem 283: 13194-13204.